Azithromycin
Brand names: Zithromax
Azithromycin is a macrolide antibiotic used in children for respiratory tract infections, certain atypical and sexually transmitted infections, and pertussis, with a long tissue half-life allowing short courses.
Adult dose
Paediatric dose
Dose adjustments
No dose adjustment is required in patients with GFR of 10 mL/min or above. In patients with GFR below 10 mL/min azithromycin should be administered with caution.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Applies to paediatric patients aged 6 months and older weighing less than 45 kg. The 10 mg/kg/day figure in dosePerKg is the regimen for ACUTE BACTERIAL SINUSITIS, COMMUNITY ACQUIRED PNEUMONIA and ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS: 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. OTHER INDICATIONS DIFFER: acute bacterial otitis media - a single dose of 30 mg/kg, or 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. Acute streptococcal tonsillitis and pharyngitis - 20 mg/kg/day for 3 days, or 12 mg/kg/day for 5 days. The SPC contains per-weight maximum daily dose tables (Table 2) and suspension volume tables for the 20 mg/ml and 40 mg/ml strengths (Tables 3 and 4) - dispensing volumes must be read from the SPC for the strength being used. There is no relevant use of azithromycin for the treatment of acute exacerbations of chronic bronchitis in paediatric patients. Safety and efficacy have not been established in children under 6 months of age for any indication. Consideration should be given to the treatment regimens, doses and duration recommended in updated treatment guidelines for each indication. Clinician to verify all paediatric doses against a children's formulary before publication.
Contraindications
- Hypersensitivity to the active substance, to erythromycin, to any macrolide or ketolide antibiotic, or to any of the excipients
Side effects
- Diarrhoea (very common)
- Vomiting, abdominal pain and nausea (common)
- Headache (common); dizziness (uncommon)
- Hypersensitivity and angioedema (uncommon); anaphylactic reaction (rare); severe cutaneous adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP
- QT prolongation, torsade de pointes and arrhythmia including ventricular tachycardia (rare); pseudomembranous colitis; hepatic failure
Interactions
- Other active substances known to prolong the QT interval - azithromycin should be used with caution in patients receiving these because of the risk of ventricular arrhythmias including torsade de pointes (section 4.4, which cross-refers to section 4.5)
- NOTE: SPC section 4.5 was not captured in this bundle; the entry above is the interaction stated within section 4.4 - the full interaction section must be checked against the SPC
Clinical monograph
How it works
It binds the bacterial 50S ribosomal subunit and inhibits protein synthesis, giving a bacteriostatic effect against susceptible organisms.
Prescribing in practice
- Azithromycin prolongs the QT interval, so avoid combining with other QT-prolonging drugs and use caution where there is known cardiac conduction risk.
- Dose by weight using a children's formulary, and be aware of an association with infantile hypertrophic pyloric stenosis when macrolides are used in very young infants.
- Gastrointestinal upset is common, and macrolides interact with several drugs metabolised through hepatic enzymes.
Monitoring
Monitor clinical response, gastrointestinal tolerance, and consider cardiac risk where other QT-prolonging factors are present.
Counselling the patient
- The course is usually short because the medicine stays in the body for some time.
- Report vomiting, especially forceful vomiting in a young infant.
- Tell the prescriber about any heart rhythm problems or other regular medicines.
Evidence & guidelines
Azithromycin features in UK guidance for pertussis and selected paediatric infections, with recognised QT-prolongation precautions.
Reference: PHE Antibiotic Guidelines; NICE NG138; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia